Brigitte Widemann
0000-0002-9198-7175
NCI, CCR
8 papers found
Refreshing results…
Imaging as an early biomarker to predict sensitivity to everolimus for progressive NF2-related vestibular schwannoma
Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromas
MEK inhibition synergizes with TYK2 inhibitors in NF1-associated Malignant Peripheral Nerve Sheath Tumors
A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma
Reporting of Racial and Ethnic Minority Representation in Early Phase Pediatric Oncology Clinical Trials
Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity
The MEK inhibitor selumetinib reduces spinal neurofibroma burden in patients with NF1 and plexiform neurofibromas
Missing publications? Search for publications with a matching author name.